Last data update: May 13, 2024. (Total: 46773 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Petrosky EY[original query] |
---|
Human papillomavirus vaccination and age at first sexual activity, National Health and Nutrition Examination Survey
Petrosky EY , Liu G , Hariri S , Markowitz LE . Clin Pediatr (Phila) 2016 56 (4) 363-370 The National Health and Nutrition Examination Survey (NHANES) collects information on human papillomavirus (HPV) vaccination history as well as sexual activity. We evaluated data from NHANES to assess report of HPV vaccination with ≥1 dose and 3 doses among females and males aged 11 to 26 years during 2007-2014. We also examined age at first vaccine dose and age at first sexual activity among females aged 14 to 26 years. Vaccination significantly increased in females aged 13 to 26 years, but not among 11- to 12-year-old girls, and remained low for both females and males. In NHANES 2011-2014, among females with known age at first vaccine dose, 43.1% reported having had sex before or in the same year they received their first HPV vaccine, and this varied by race/ethnicity. Clinicians should provide strong recommendations consistent with guidelines, including routine vaccination of girls and boys at age 11 or 12 years. |
Is vaccine type seropositivity a marker for human papillomavirus vaccination? - National Health and Nutrition Examination Survey, 2003-2010
Petrosky EY , Hariri S , Markowitz LE , Panicker G , Unger ER , Dunne EF . Int J Infect Dis 2015 33 137-41 OBJECTIVE: Since 2006, human papillomavirus (HPV) vaccination has been routinely recommended for U.S. adolescent females. The quadrivalent vaccine induces long-term seropositivity to HPV 6/11/16, which may be useful as a marker of HPV vaccine coverage. METHODS: We evaluated vaccine type seropositivity (i.e., seropositivity to HPV 6/11/16 with or without HPV 18) among females aged 14-59 years participating in 2003-2010 National Health and Nutrition Examination Survey (cross-sectional, nationally representative surveys). We compared pre-vaccine era (2003-2006) to vaccine era (2007-2010) seropositivity and assessed agreement between vaccine era seropositivity and reported vaccination by kappa statistic. RESULTS: Seropositivity was 1.0% among 2,151 females in the pre-vaccine era and 22.1% among 1,420 females in the vaccine era (P <0.001); 23.1% of vaccine era females reported receipt of ≥1 HPV vaccine dose. Seropositivity and reported vaccination had high agreement (kappa=0.79; 95% confidence interval: 0.74-0.84). Among seropositive females, 14.5% reported no vaccination. CONCLUSION: The increase in vaccine era seropositivity likely reflects vaccination uptake. Our study suggests seropositivity to HPV 6/11/16 may be a useful marker of vaccination coverage in adolescent and young adult females. Discordance between seropositivity and reported vaccination may be explained by inaccurate reporting and/or natural exposure to HPV. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 13, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure